110 results about "Increased Lipolysis" patented technology

A method of lipolysis. The method comprises deforming a region of skin so that the region of skin protrudes from surrounding skin. One or more radio frequency (RF) electrodes are positioned on the protruding region of skin so as to generate an electrical current through adipose tissue in the protruding region of skin when a voltage is applied to the electrode or electrodes. A voltage is then applied to the electrode or electrodes so as to deliver sufficient RF energy to the protruding region of skin to damage subcutaneous adipose tissue. The method of the invention may be used, for example, to achieve a reduction in body weight, cellulite reduction, loose skin reduction, wrinkle treatment, body surface tightening, skin tightening, and collagen remodeling.

The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.

A lipolysis system configured for contacting and providing low-power laser irradiation to a plurality of targeted portions of a subject's body surface for the purpose of liquefying fats in subcutaneous regions underlying the targeted body surface portions, and methods for the use of the lipolysis system. The lipolysis system comprises: (a) a first laser applicator comprising a plurality of low-power laser diodes selected for emission of power outputs in the range comprising about 10 mW to about 100 mW with light waves in the range of 635 nm to 680 nm, (b) a second laser applicator comprising at least one low-power laser diode selected for emission of power outputs in the range comprising about 10 mW to about 100 mW with light waves in the range of 635 nm to 680 nm, and (c)a laser control device configured for controllably communicating and cooperating with said first laser applicator and said second laser applicator.

A device includes light sources, electromagnetic field generators, and vibration components to apply a variety of treatment regimens to a living animal organism, including a human person or a body part of a person. The light and electromagnetic therapy are applied at frequencies which have physiological effects, and which can be combined to induce lipolysis, stimulate muscle, and achieve other effects. Feedback is used to dynamically adjust the intensity, duration, and other parameters of the light, electromagnetic, and vibration treatment modalities.

The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.

The present invention is directed to a lipolysis stimulator and a slimming agent which stimulate or facilitate lipolysis of accumulated adipose tissue, to thereby exert the body slimming effect. The lipolysis stimulator or the slimming agent of the present invention contains as an active ingredient any form of a plant or an extract thereof, the plant being selected from among common juniper, togenashi, rosehip, areca, polygala root, plantago herb, calumba, zuikorodoku, garden nasturtium, kidachiumanosuzukusa, bayberry, cogon grass, kohon, shoyokanzo, Japanese white birch, tanjin, kikubafuro, white mustard, common sunflower, ground ivy, Chinese wolfberry, Japanese pagota tree, sennenken, common fig, kankatto, Chinese hibiscus, usubaakaza, fenugreek, English walnut, sozuku, koniwa-zakura, gardenia, shima-kan-giku, akamino-akane, futaba-mugura, karoou, schizonepeta spike, purslane, karabyakushi, and prostrate knotweed.

The present invention relates to a .beta..sub.3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof, which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type II diabetes and / or obesity. The compound can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compound can be used to reduced neurogenic inflammation or as an antidepressant agent. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for decreasing gut motility are also disclosed.

The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.

The present invention relates to a fusion peptide wherein a self cell-penetrating Tat peptide having a self penetrating signal is bound to a human parathyroid hormone-derived peptide, a preparation thereof, and a skin slimming cosmetic composition comprising the same. Since the fusion peptide wherein the Tat peptide is bound to the human parathyroid hormone-derived peptide has high stability and superior skin absorption, the present invention provides a skin slimming agent having superior lipolysis effects and improved durability of the effects.

Methods and pharmaceutical compositions useful for modulating lipoprotein levels in vivo. The invention stems from the discovery that activity of the Lipolysis Stimulated Receptor (LSR) can be inhibited or enhanced by exogenous agents, including polypeptides.

The invention discloses a slimming food for changing lipophilic physique and a processing method thereof and relates to a slimming food. The slimming food for changing lipophilic physique is prepared from the following raw materials: probiotics, prebiotics, dietary fibers and fruits and vegetables in a mass ratio of (0.1-40):(0.5-50):(0-15). The processing method comprises the following steps: firstly, drying the raw materials; then, uniformly mixing the raw materials; quantitatively packaging or respectively packaging the raw materials to obtain the slimming food. The slimming food can be used for changing the structure of intestinal flora essentially, reducing and inhibiting the quantity of firmicutes easily hoarding fat and increasing the quantity of bacteroides which facilitate lipolysis and control heat absorption so as to fundamentally change the lipophilic physique, so that the weight of control body weight crowd is efficiently controlled and rebounding after weight reduction is prevented. The slimming food is convenient to eat, can be used with drinking water or diet every day, and is easy to insist.

The invention discloses methods for the chronic administration of adenosine, which contrary to the acute delivery of the drug by injection or infusion, acts in desensitizing adenosine receptors towards the action of adenosine. The methods and oral compositions of adenosine triphosphate (ATP), which is degraded to adenosine in vivo, can be used in the treatment of disorders and diseases that are therapeutically targeted by agonists or antagonists of adenosine receptors. One example is the stimulation of lipolysis in achieving weight loss in humans and in the treatment of obesity.

A novel, new, and highly effective agent for promoting fat degradation that contains astaxanthin and / or an ester thereof as active ingredient is provided. The agent for promoting fat degradation of the present invention has an effect of reducing fat by lipolysis of fat in either a subject who is in a condition in which fat has already accumulated or a subject who is in a condition in which fat has not yet been accumulated. Accordingly, the agent for promoting fat degradation of the present invention can restore hypertrophied adipocytes to a normal size.

The invention discloses a laser lipolysis system. The system comprises a laser module, a controller, a cooling component, an operation optical fiber device and an optical fiber connector, wherein the laser module comprises a first laser component and a second laser component; a first laser is a visible wavelength laser for indicating a radiation region, a second laser is an infrared wavelength laser for lipolysis, and the wavelength of the first laser is different from that of the second laser. The laser lipolysis system can be used for outputting lasers with two wavelengths, and an elliptical laser beam output by utilizing a flat round optical fiber can be used for quickly, smoothly and safely dissolving fat in a thin fat layer. By means of an optical fiber identification system, initial data in a radio frequency transmission memory can be inquired through a radio frequency reader-writer, the manufacture and state of an operation optical fiber can be identified, new data is saved according to use records, and disposable use of the optical fiber can be identified and controlled by the controller, so that cross infection can be avoided.

Methods for increasing lipolysis in a cell are described herein. Such methods comprise the application of an electrical current to a cell. In an embodiment, the application of the electrical current does not substantially alter the viability of such cell and / or preserves the viability of such cell. In an embodiment, such cell is an adipocyte. Corresponding uses and packages are also described.

A pharmaceutical composition including, as an active ingredient, one of the following proteins (I) and (II): (I) an apoptosis inhibitor of macrophage; and (II) a protein which consists of an amino acid sequence having deletion, substitution, or addition of one or more amino acids in an amino acid sequence of the apoptosis inhibitor of macrophage and having homology to the amino acid sequence of the apoptosis inhibitor of macrophage, and has a function of inhibiting the differentiation of preadipocytes to mature adipocytes and / or a function of inducing lipolysis in the mature adipocytes.

The invention provides analogs of PYY. The invention also provides compositions and methods useful for controlling biological activities such as cell proliferation, nutrient transport, lipolysis, and intestinal water and electrolyte secretion.

An improved formulation and method for the removal of subcutaneous fat deposits in a human in need of such treatment. It also induces an inflammatory reaction which treats disorders of tissue adhesion which often accompany subcutaneous fat deposits or are created in the process of removal of subcutaneous fat deposits. This inflammatory reaction also limits the extent of the effect of the injected medication to a localized area. A lecithin and aqueous glucose and sodium chloride based biphasic injection dosage formulation is disclosed which is applicable to subcutaneous, intramuscular, and intravenous administration. Additionally, a program based approach to the treatment of subcutaneous fat deposits which includes injections of this formulation, application of compression garments, diet modification, and exercise is described. The formulation is characterized in that it comprises an adjustable acidifying agent to set pH, an antioxidant, a sclerosing agent, and a stabilizer. It is further characterized in that it includes liposomes, and that the components of these liposomes are therapeutic in the treatment of several human ailments. It is also efficacious in the treatment of striae albicantes, striae atrophicae, cellulite, and decreased skin turgor.

A method for the identification of a composition useful in the treatment of an overweight or obese person to reduce the person's body mass index is provided which comprises obtaining an extract of an ethnobotanical plant, and evaluating the activity of the extract in an assay selected from the group consisting of a lipolysis assay, an assay that measures the amount of glycerol introduced by a cell into a suspension medium of the cell, an adipocyte differentiation assay, an assay that measures the level of the enzyme glycerol-3-phosphate dehydrogenase, an assay that measures the inhibition of differentiation of preadipocytes to adipocytes, an assay that measures the accumulation of lipid in an adipocyte, an assay that measures the de-differentiation of adipocytes into preadipocytes, and combinations thereof. Sclareol and sclareol-like compounds and sclareolide and sclareolide-like compounds are identified as useful in the treatment of overweight and obese conditions and disorders and conditions associated with adipose tissue abnormalities. These compounds can be formulated for oral administration.

[Problem to be solved] To provide a naturally-derived lipolysis promoter with high safety, which may promote the degradation of the accumulated adipose tissue to control, prevent, and ameliorate obesity to a satisfactory extent. [Solution] A lipolysis promoter containing one kind, or two or more kinds of plant bodies and / or extracts therefrom selected from the group consisting of Myristica fragrance, Symplocarpus foetidus, Escholzia california, Sparganium stoloniferum, Sanguinaria canadensis, Mahonia Aquifolium, Acorus gramineus, the fruit site of Musa paradiciaca, Cytisus scoparius, Hydrastis canadensis, Ficaria ranunculoides, Fumaria officinalis, Unonopsis floribunda, Nasturtium officinale, Nigella sativa, Urtica dioica, Capsella bursa-pastoris, and Polygonum bistorta as active ingredients.

An improved formulation and method for the removal of subcutaneous fat deposits in a human in need of such treatment. It also induces an inflammatory reaction which treats disorders of tissue adhesion which often accompany subcutaneous fat deposits or are created in the process of removal of subcutaneous fat deposits. This inflammatory reaction also limits the extent of the effect of the injected medication to a localized area. A lecithin and aqueous sodium chloride based biphasic injection dosage formulation is disclosed which is applicable to subcutaneous, intramuscular, and intravenous administration. Additionally, a program based approach to the treatment of subcutaneous fat deposits which includes injections of this formulation, application of compression garments, diet modification, and exercise is described. The formulation is characterized in that it comprises an adjustable acidifying agent to set pH, an antioxidant, a sclerosing agent, and a stabilizer. It is further characterized in that it includes liposomes, and that the components of these liposomes are therapeutic in the treatment of several human ailments. It is also efficacious in the treatment of striae albicantes, striae atrophicae, cellulite, and decreased skin turgor.

The present invention relates to a composition containing genistein that accelerates the expression of the Carnitine Palmitoyl Transferase-1 (CPT-1) for improving or treating obesity. More particularly, the composition of the present invention comprises genistein that accelerates the expression of the CPT-1, an important enzyme for the lipolysis of fatty acid, and comprises carnitine that transports fatty acid into mitochondria and accelerates oxidation of fat in the oxidation process of fatty acid.

Compositions for controlling mammalian weight, said compositions comprising one or more lipolytic agents for stimulating mammalian lipolysis and / or thermogenic agents for modulating mammalian thermogenesis. Products, consumer and otherwise, comprising said compositions and methods of using both the present compositions and products to control mammalian weight.

A cosmetic composition according to the present invention may prevent the precipitation of caffeine at a low temperature, and thus may comprise a high concentration of caffeine that is effective in promoting lipolysis. Caffeine is known to promote lipolysis when applied to a human body. The cosmetic composition of the present invention may comprise a high concentration of caffeine, and thus can be valuably use in cosmetics or the like that requires effects of caffeine such as slimming effects, effect of relief from facial swelling or the like.

The invention discloses a medical instrument for slimming, in particular to a super lipolysis slimming instrument which is characterized by comprising a handle. A motor is mounted in the handle and connected with a power plug, a rotating shaft of the motor is connected with a direction converter which is connected with a three-dimensional vibration generator, and the three-dimensional vibration generator is connected with a liposuction conduit. The super lipolysis slimming instrument has simple structure and smart design, dissolves and sucks adipose tissues by utilizing super vibration at the front end of the liposuction conduit to achieve the slimming aim without damaging veins and nerves under the skin, has low manufacture cost, light injury, good slimming effect and short recovery time, brings little pain to patients and is beneficial to popularizing and applying in a large range.

The invention discloses essence containing plankton and an application of the essence in cosmetics. The essence contains plankton extract, hop extract, capsicum frutescens fruit extract, ruscus aculeatus root extract and solidago virgaurea extract. The mass ratio of plankton extract to hop extract to capsicum frutescens fruit extract to ruscus aculeatus root extract to solidago virgaurea extract is (3-9) g:(2-6) g: (1-5) g: (1-3) g: (1-3) g. The essence and the cosmetics containing the essence comprehensively act on various fat cells, lipolysis is promoted, accumulation of fat is avoided, local microcirculation disturbance is eliminated, edema is eliminated, leg fatigue and heaviness are relieved, and remarkable moisturizing, slimming and local slimming effects are achieved.

The invention provides methods, therapeutics and kits for treating and preventing diseases or conditions associated with excessive lipolysis, in particular TNF-α induced lipolysis, and / or excessive free fatty acid levels. Exemplary conditions include insulin-resistance, diabetes, in particular NIDDM, obesity, glucose intolerance, hyperinsulinemia, polycystic ovary syndrome, and coronary artery disease. In a preferred embodiment, the method includes administering to a subject in need a pharmaceutically effective amount of an inhibitor of the JNK signal transduction pathway and / or an inhibitor of the MAPK / ERK signal transduction pathway.